Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
Ryan R CookC FootO A ArahK HumphreysK E RudolphS X LuoJ I TsuiX A LevanderP T KorthuisPublished in: Addiction science & clinical practice (2023)
Stimulant use is a barrier to buprenorphine or XR-NTX initiation in clinical trials and real-world populations that would benefit from OUD treatment. Interventions to address stimulant use among patients with OUD are urgently needed, especially among rural people injecting drugs, who already suffer from limited access to MOUD.